Call Us: +91925476854
Explore clinically focused review articles designed to help physicians refine patient selection, understand risk factors, optimise SWL protocols, and apply evidence-based decision-making in daily stone management.
Background: Children are not small adults: their anatomical proportions, physiological responses, metabolic determinants of stone disease, behavioral requirements during procedures, and — critically — the long-term implications of any renal parenchymal injury on a still-developing kidney demand a distinctly tailored approach to extracorporeal shock wave lithotripsy (ESWL). First applied to children by Newman et al. in 1986, ESWL is now established as first-line treatment for most upper urinary tract stones ≤ 15–20 mm in the pediatric population. The pediatric urinary system confers biological advantages — reduced skin-to-stone distance, more distensible ureters, and lower stone density — that in some respects make children better ESWL candidates than adults. However, the universal 100% high-recurrence-risk classification of all pediatric stone patients (EAU 2024; AUA 2025), the mandatory anesthesia requirement, the heightened radiosensitivity of children, and the ongoing question of cumulative shock wave effects on the growing kidney collectively demand a more deliberate and protocol-driven approach than in adult lithotripsy practice.
Objectives: This article provides a comprehensive, evidence-based framework for ESWL in children, addressing: the epidemiology and stone composition profile of pediatric urolithiasis; efficacy data including predictors of success; the absolute anesthesia imperative and validated sedation protocols; the ALARA radiation protection principle applied to targeting and follow-up imaging; the short- and long-term renal safety evidence for the growing kidney; the critical distinction between clinically insignificant residual fragments in adults versus children; and a practical clinical protocol for pre-procedure assessment, intraoperative technique, post-procedure management, and modality selection.
Methods: A structured narrative review was conducted incorporating the Lu et al. systematic review and meta-analysis of pediatric ESWL efficacy (Urolithiasis 2015; PMID: 25721456); the Hasaneen et al. 500-case series (PMID: 22350835); the El-Assmy et al. adult-versus-child comparative study (PMID: 18727616); a 2026 Frontiers in Pediatrics randomized comparison of stepwise energy escalation versus fixed-energy protocols in 81 children (doi: 10.3389/fped.2026.1736104); the Cevik et al. 10-year anesthesia retrospective analysis of 408 ESWL sessions in 251 children (PMID: 28642966); the Griffin et al. 20-year long-term safety series (PMID: 20400129); the Vlajković et al. GFR trajectory study; the Swiss long-term cohort of 70 pediatric patients; the Akin and Yucel narrative review of 3,000 articles (PMC: PMC4011895); the Afshar et al. residual fragment outcome study; and the 2024 EAU and 2025 AUA urolithiasis guidelines.
Results: Published stone-free rates for pediatric ESWL range from 67–93% at three months, with stones < 10 mm achieving significantly higher rates than larger stones (pooled RR 1.14; 95% CI 1.07–1.21; p < 0.001) and proximal ureteric stones outperforming mid/distal locations (RR 1.077; p = 0.036). Children achieve equivalent stone-free rates to adults while requiring significantly fewer and lower-energy shock waves (p < 0.01), confirming the fundamental advantage of reduced body habitus. A 2026 Frontiers RCT demonstrated that stepwise energy escalation achieves significantly higher first-session stone-free rates (73.2% vs 55.0%) and 3-month rates (95.1% vs 87.5%) compared to fixed-energy protocols without additional morbidity. All children up to approximately 14 years require general anesthesia or deep procedural sedation; ketamine-midazolam combination sedation was validated across 408 ESWL sessions in 251 children aged 7 months to 14 years with no severe complications. Long-term renal safety is supported by four decades of follow-up data: the Griffin 20-year series found no permanent renal scarring or long-term renal function loss; Vlajković et al. demonstrated complete GFR recovery by 3 months after a transient post-ESWL reduction; the Swiss 70-patient cohort confirmed no hypertension, no diabetes, and no impaired renal growth attributable to ESWL. However, residual fragments deemed clinically insignificant in adults carry a high progression risk in children: 69% of residual fragments ≤ 5 mm and 33% of fragments < 3 mm showed increasing stone mass on follow-up, making complete clearance — not fragment reduction — the correct treatment endpoint. Cystine stones are an absolute ESWL contraindication in children and require redirection to ureteroscopy with holmium laser lithotripsy.
Conclusions: ESWL is a safe, effective, and non-invasive first-line treatment for upper urinary tract stones ≤ 15 mm in children, with a long-term safety record that does not support permanent harm to the growing kidney when protocol-optimized. The non-negotiable pillars of safe pediatric ESWL practice are: general anesthesia or deep procedural sedation for every session; ultrasound-guided targeting to minimize radiation exposure (ALARA); shock wave rate reduction to 60/min or below; mandatory stepwise energy escalation; a maximum of three sessions before modality reassessment; complete metabolic evaluation in all children (EAU 2024 guideline); and a stringent stone-free rate standard at three months that treats any fragment > 3–4 mm as treatment failure requiring active management. Ureteroscopy under a single anesthetic should be preferred over multiple ESWL sessions for cystine stones, stones > 15–20 mm, and cases of failed ESWL, to minimize cumulative anesthetic burden, radiation exposure, and renal parenchymal injury.
The pediatric patient presenting with urinary stone disease occupies a special and demanding position in lithotripsy practice. Children are not small adults — their anatomical proportions, physiological responses, metabolic underpinnings of stone disease, behavioral characteristics during procedures, and the long-term implications of any renal parenchymal injury on a still-developing kidney all demand a distinctly tailored approach to ESWL. At the same time, the pediatric urinary system offers certain biological advantages that make children, in some respects, better candidates for ESWL than adults: their smaller body habitus reduces skin-to-stone distance, their more distensible ureters facilitate passage of fragments, and their lower stone density frequently confers greater shock wave susceptibility.
ESWL was first successfully used in the pediatric population by Newman et al. in 1986 — six years after its introduction in adults — after a cautious period during which manufacturers initially recommended treatment only for patients taller than 135 cm. Since then, a large and growing body of evidence has established ESWL as first-line treatment for most upper urinary tract stones ≤ 15–20 mm in children, with stone-free rates, safety profiles, and long-term renal outcomes that are now well-characterized across nearly four decades of experience.
This article reviews the evidence base for ESWL in children comprehensively: the biology of pediatric stone disease, the factors predicting success, the question of anesthesia, the short-term and long-term safety data, and a practical clinical protocol for pediatric ESWL drawn from the literature and from personal experience. The specific concerns about growing kidney injury — the question that has most exercised practitioners — are addressed in detail.
Children constitute approximately 1% of all patients with urolithiasis in developed countries, with prevalence estimates in the United States ranging from 1 in 1,000 to 1 in 7,600, depending on geography and demographics. However, prevalence has been increasing dramatically over the past two decades — a trend observed across multiple countries and healthcare systems, particularly in adolescents. This increase mirrors trends in adult stone disease and has been attributed to rising rates of obesity, dietary changes (increased sodium, reduced fluid intake), antibiotic use, and possibly climate change-related increased ambient temperatures.
A critical and defining feature of pediatric stone disease — one that distinguishes it fundamentally from adult stone disease — is that 100% of children with urolithiasis are considered high risk for stone recurrence. This designation, which carries consensus across both EAU and AUA guideline panels, reflects the high prevalence of identifiable metabolic and anatomical predisposing factors in the pediatric population: hypercalciuria (the most common metabolic abnormality), hyperoxaluria, cystinuria, primary hyperparathyroidism, distal renal tubular acidosis, and structural urinary tract abnormalities each contribute to stone recurrence. This high-recurrence context has a direct implication for ESWL: achieving complete stone clearance — not merely adequate fragmentation — is paramount in children, because any residual fragments serve as a nidus for recurrence.
Unlike adult stone disease, which is predominantly calcium oxalate monohydrate (CaOx-MH), pediatric stone composition is more heterogeneous and more strongly linked to underlying metabolic abnormalities. Calcium phosphate stones are proportionally more common in children than in adults, reflecting the higher prevalence of hypercalciuria and renal tubular abnormalities. Cystine and struvite stones, which are relatively rare in the adult population, together account for a substantially higher fraction of pediatric calculi. This compositional profile matters for ESWL in two important respects: (1) calcium phosphate stones (particularly brushite) are harder and more resistant to fragmentation than calcium oxalate dihydrate or uric acid stones; (2) cystine stones are notoriously resistant to shock waves and represent a well-recognized indication for ureteroscopy or PCNL over ESWL; (3) struvite stones are associated with active infection and require antibiotic management alongside any stone treatment.
A comprehensive German study of pediatric stone composition involving 64 children with 83 upper urinary tract stones treated with ESWL (Lithostar, Storz) from 1990–1998 found the distribution as follows: 20 calcium oxalate stones (30%), 38 calcium phosphate stones (58%), 12 struvite stones (18%), 2 uric acid stones (3%), and 9 cystine stones (14%) — with overlap in mixed stones. Stone analysis before ESWL is not merely academic: it directly determines whether ESWL is the appropriate modality and what energy parameters should be expected to achieve fragmentation.
The efficacy of ESWL in pediatric urolithiasis is well-supported across multiple large series and systematic analyses. Published stone-free rates range from 67% to 93% at short-term follow-up (≤3 months) and from 57% to 92% at long-term follow-up, reflecting the influence of stone size, location, composition, lithotripter technology, and the definition of stone-free status used.
A 2015 systematic review and meta-analysis by Lu, Wang, Song et al. (Urolithiasis, 2015; PMID: 25721456) comprehensively synthesized the available evidence from PubMed, EMBASE, and Cochrane databases. Using pooled risk ratios, the key findings were:
A large series of 500 children treated with ESWL using the Siemens Lithostar Modularis (Sohag University, Egypt; PMID: 22350835) reported an overall success rate of 83.4% for renal calculi and 58.46% for ureteral calculi. The re-treatment rate was 4% in the renal group and 28% for the ureteral group. Notably, no serious complications were recorded in the entire cohort; minor complications (renal colic 10%, vomiting 5%) occurred in 15% of patients and were managed conservatively.
A direct adult-versus-child comparison by El-Assmy et al. (PMID: 18727616) using an electromagnetic lithotripter over a 5-year period compared 44 children (mean age 5.9 years) with 562 adults for solitary renal and upper ureteric stones < 2 cm. The finding of central importance to pediatric ESWL practice was: children achieved equivalent stone-free rates to adults while requiring significantly fewer and lower-energy shock waves (p < 0.01 for both). This confirms the fundamental biological advantage of the pediatric patient — less body mass to attenuate shock wave energy, resulting in superior focal zone delivery with less total energy input.
The pivotal shift in thinking about low-dose aspirin and ESWL was catalyzed by a systematic Medline/PubMed literature review from the Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Germany, published in Journal of Endourology (Netsch, Bach, Buchholz et al., 2014; PMID: 24851726). This review comprehensively searched peer-reviewed literature on anticoagulative and antiplatelet medication management during SWL and reached the following key conclusions:
The real-world picture of how endourologists manage aspirin during ESWL was captured in a survey of approximately 2,000 members of the Endourology Society conducted in September 2016 (published in Journal of Urology, 2017). Of 184 substantive responses from six continents:
The paradox revealed by this survey is striking: ureteroscopy — an endoscopic procedure requiring ureteral access, instrumentation, and laser energy delivery — is performed by 79% of endourologists on aspirin, while ESWL — a completely non-invasive procedure — is performed on aspirin by only 18%. This inversion of perceived risk is not supported by the comparative hemorrhage literature, where subcapsular hematoma rates for URS are also reported (Bai et al., Chiu et al.), and it reflects historical precedent and convention more than contemporary evidence-based practice.
The most clinically important classification to establish when managing any antiplatelet patient for ESWL is whether they are on aspirin monotherapy (low-dose, 75–150 mg/day) or on dual antiplatelet therapy (DAPT) — aspirin combined with a P2Y12 inhibitor. These are categorically different clinical scenarios with fundamentally different risk profiles, different cardiovascular indications, and different management imperatives.
Low-dose aspirin monotherapy for primary or secondary cardiovascular prevention is a relatively low-risk interruption scenario — aspirin cessation is associated with an odds ratio of 3.1 for cardiac complications (peaking at 10 days after cessation), but this primarily represents a rebound platelet hyperaggregability phenomenon and is manageable with a brief washout period of 5–7 days when clearly indicated by the clinical context. DAPT, by contrast, is prescribed for a specific and time-critical reason: prevention of stent thrombosis following coronary stenting. Clopidogrel cessation is the most significant independent predictor of stent thrombosis, with an odds ratio of 14–57 during the first 18 months after drug-eluting stent implantation. Stopping DAPT within the first 6 weeks after stenting carries a cardiovascular mortality of up to 71% in some published series — a figure that dwarfs any conceivable ESWL-induced hemorrhage mortality.
The reason DAPT is prescribed after coronary stenting is straightforward: bare metal stents are covered by smooth muscle cells within 6 weeks and by normal endothelium within 3 months. Drug-eluting stents have a profoundly slower endothelialization rate — 13% at 3 months and only 56% at 3 years — because the antiproliferative drug coating that prevents restenosis also impairs the natural healing process. Until endothelialization is complete, the metallic stent struts are exposed to flowing blood; without antiplatelet coverage, platelet aggregation on these bare metal surfaces leads to late stent thrombosis — a rare (0.6% per year after DES) but catastrophic event with a mortality of 19–45%.
The 2016 ACC/AHA guideline update on DAPT duration after PCI represents the current standard of care: for patients with stable ischemic heart disease treated with a DES, a minimum of 6 months of DAPT with clopidogrel is recommended, with just 3 months considered for those at high bleeding risk. For patients with acute coronary syndrome (ACS) treated with DES, 12 months of DAPT is the minimum recommended duration, with longer durations considered for high-ischemic-risk patients. The prior Class I recommendation requiring delay of all elective noncardiac surgery for 1 year after DES has been modified: the guideline now recommends delaying elective noncardiac surgery for at least 6 months after DES placement.
For the lithotripsy context, these timelines generate a direct clinical framework: a patient presenting with a symptomatic renal stone within 6 months of DES placement is in the highest-risk category for DAPT interruption. Elective ESWL should be deferred if clinically possible. If the stone requires treatment (obstruction, intractable pain, infection), ureteroscopy while maintaining DAPT — despite its own bleeding risks — may paradoxically be the safer choice because it offers definitive single-session treatment without requiring antiplatelet cessation, unlike ESWL which may require multiple sessions.
The most recent rigorous RCT addressing aspirin management in patients with DES undergoing noncardiac surgery was the ASSURE-DES trial (Journal of the American College of Cardiology, 2024), which randomized patients who had received a DES > 1 year previously and were undergoing elective noncardiac surgery either to continue aspirin or discontinue all antiplatelet agents 5 days before surgery. The primary outcome was a composite of death, MI, stent thrombosis, or stroke at 30 days. The result: no stent thrombosis occurred in either group. The incidence of major bleeding did not differ significantly between groups (6.5% vs 5.2%; p = 0.39), while minor bleeding was more frequent in the aspirin group (14.9% vs 10.1%; p = 0.027). The trial failed to demonstrate a significant difference in ischemic outcomes between perioperative aspirin continuation and cessation in this specific population — though the authors acknowledged that the event rates were lower than expected, limiting statistical power.
This trial, while not ESWL-specific, is relevant to the ESWL management framework: it suggests that for patients beyond 1 year from DES implantation undergoing low-to-intermediate risk procedures, the absolute ischemic risk of temporary aspirin cessation is lower than historically feared — and the absolute hemorrhagic risk of continuation is also modest. For ESWL specifically, the procedure’s non-invasive character places it firmly in the low-to-intermediate bleeding risk category.
An important and clinically under-appreciated phenomenon relevant to all antiplatelet cessation decisions is the aspirin withdrawal syndrome: a rebound prothrombotic state that follows aspirin discontinuation, characterized by increased thromboxane A2 synthesis, elevated platelet aggregation, and increased platelet-leukocyte interaction. This rebound phenomenon peaks at 8–10 days after aspirin cessation and explains the temporal clustering of cardiovascular events in the 10-day window following aspirin withdrawal. For a patient with established coronary artery disease, this physiological rebound coincides precisely with the period during which ESWL is being performed if aspirin is withheld for the standard 7-day pre-procedure period — a timing concern that has not been adequately addressed in the urological literature.
Every patient on antiplatelet therapy presenting for ESWL should be classified into one of three risk tiers before any decision about antiplatelet management is made. This classification is based on the nature of the cardiovascular indication, not merely the drug being taken.
| Risk Tier | Patient Profile | ESWL Management Principle |
|---|---|---|
| Tier 1 — Low Cardiovascular Risk | Low-dose aspirin 75–150 mg/day for primary or secondary prevention (no coronary stent, no recent ACS); stable coronary artery disease > 12 months from any revascularization; peripheral arterial disease on aspirin only; atrial fibrillation on aspirin only. | ESWL with continued low-dose aspirin is increasingly defensible based on Regensburg evidence. If institutional protocol requires cessation: withhold aspirin 5–7 days. Cardiology consultation recommended but not mandatory for primary prevention patients. Restart aspirin 24–48 hours post-ESWL. |
| Tier 2 — Intermediate Cardiovascular Risk | DAPT (ASA + P2Y12 inhibitor) > 12 months after DES implantation; DAPT for bare metal stent > 6 months; history of stroke/TIA on DAPT; peripheral arterial disease on DAPT. | Cardiology consultation mandatory before any antiplatelet decision. For ESWL: P2Y12 inhibitor withheld per guideline timeline (clopidogrel/ticagrelor 5 days; prasugrel 7 days); aspirin continued. Resume P2Y12 inhibitor 24–48 hours post-ESWL. Ureteroscopy is a reasonable alternative to avoid interruption. |
| Tier 3 — High Cardiovascular Risk | DAPT within 6 months of DES implantation; DAPT within 3 months of ACS (even without stent); DAPT within 6 weeks of any coronary intervention; recent ischaemic stroke (< 3 months) on DAPT. | ESWL is RELATIVELY CONTRAINDICATED as an elective procedure. Defer ESWL until beyond the high-risk DAPT window if clinically possible. If stone is symptomatic/obstructing: ureteroscopy on DAPT is preferred over ESWL requiring interruption. If ESWL is absolutely necessary: proceed on full DAPT with intensified hemorrhage monitoring; cardiology must be involved and document risk acceptance. |
| Parameter | Modification for Antiplatelet Patients |
|---|---|
| Shock wave rate | Reduce to 60/min — minimizes cumulative vascular trauma per session |
| Energy ramping | Mandatory stepwise escalation — begin at lowest effective energy, titrate upward. Do not start at maximum voltage. |
| Total shock waves per session | Strict limit of ≤ 2,000 shock waves per session for antiplatelet patients — lower total energy delivery reduces parenchymal injury |
| Session spacing | Minimum 14 days between sessions — allows adequate renal recovery before the next shock wave exposure |
| Maximum number of sessions | Plan for ≤ 3 sessions; if not achieving adequate fragmentation, reassess modality choice (URS offers lower parenchymal hemorrhage risk) |
| Baseline hematocrit | Document pre-procedure hematocrit. Any drop > 3 g/dL post-ESWL warrants urgent imaging evaluation. |
| Bilateral stones | Do NOT treat bilateral renal stones in the same ESWL session in antiplatelet patients — bilateral hematoma is rare but documented (Ruiz & Saltzman case) |
| Coupling | Meticulous coupling with no air pockets — reduces energy scatter, lowers peak pressures reaching perinephric tissue |
A particularly common and challenging scenario is the patient who presents acutely with a symptomatic renal or ureteric stone while on long-term low-dose aspirin for secondary cardiovascular prevention — for example, a 65-year-old with a history of myocardial infarction on 75 mg aspirin who presents with an obstructing proximal ureteric stone. The stone requires treatment; the cardiovascular indication for aspirin is established. For this patient, ureteroscopy with holmium laser lithotripsy while maintaining aspirin is supported by the current evidence and the Endourology Society survey data showing 79% of endourologists proceed with URS on aspirin. If ESWL is preferred — either because the stone is renal, the patient is obese making URS technically demanding, or patient preference — proceeding on low-dose aspirin with protocol modifications (rate reduction, limited shock waves) is a defensible position supported by the Regensburg evidence-based review.
Patients on warfarin or NOACs (apixaban, rivaroxaban, dabigatran, edoxaban) occupy a distinct category from antiplatelet patients and are addressed here briefly for completeness. Uncorrected anticoagulation is an absolute contraindication to ESWL. For warfarin patients, the INR must be corrected to ≤ 1.5 before ESWL proceeds — typically requiring 3–5 days of warfarin cessation with documented INR on the day of the procedure. For NOAC patients, the drug must be withheld for a minimum of 24–48 hours (renal-function-dependent for dabigatran; hepatic-function considerations for rivaroxaban/apixaban) before ESWL. The decision to bridge anticoagulation with LMWH during NOAC/warfarin cessation is a cardiology and hematology decision based on the underlying thromboembolic indication — it is not routinely necessary for most AF patients undergoing brief anticoagulant interruption for ESWL.
The delayed perinephric hematoma case recently reported in ScienceDirect (2025) — a 58-year-old with hypertension, diabetes, and long-term anticoagulation who developed a massive hematoma one week after ESWL — illustrates that hemorrhagic complications in anticoagulated patients can be delayed, clinically occult until symptomatic, and of substantial magnitude. This case underscores the imperative of post-procedure imaging surveillance in all anticoagulated patients rather than symptom-driven evaluation.
A frequently overlooked risk factor is the use of non-steroidal anti-inflammatory drugs (NSAIDs) as analgesics during or immediately after ESWL. NSAIDs inhibit COX-1 in a dose- and duration-dependent (but reversible, unlike aspirin) manner, impairing platelet function for 24–72 hours after each dose. Administering ibuprofen, diclofenac, or ketorolac to a patient who is already on low-dose aspirin creates a combined platelet inhibition that is clinically significant. In ESWL patients: avoid NSAIDs as analgesics for the procedure itself and for 48–72 hours post-ESWL wherever possible. Paracetamol (acetaminophen) and opioid analgesia are the preferred alternatives.
| Contraindication Type | Condition |
|---|---|
| Absolute | Uncorrected coagulopathy: INR > 1.5, platelet count < 80,000/μL — correct before proceeding |
| Absolute | Full anticoagulation (warfarin, NOAC) at therapeutic levels at time of ESWL — must be withheld and INR/drug levels confirmed before proceeding |
| Absolute | Active bleeding diathesis (haemophilia, von Willebrand disease) — correct factor deficiency before ESWL; haematology co-management required |
| Relative | DAPT within 6 months of DES implantation — defer elective ESWL; prefer URS if treatment urgent |
| Relative | DAPT within 3 months of ACS — defer ESWL; cardiology mandatory before any antiplatelet decision |
| Relative | Any antiplatelet therapy + uncontrolled hypertension — treat hypertension first; compound risk is substantially elevated |
| Relative | Any antiplatelet therapy + diabetes + elevated BMI — triple additive risk; reduced shock wave parameters mandatory; vigilant post-procedure surveillance |
| Not a contraindication (with caution) | Low-dose aspirin monotherapy (75–150 mg/day) in Tier 1 patient — Regensburg evidence supports ESWL as an option with protocol modifications |
| Not a contraindication (with caution) | DAPT > 12 months from DES in Tier 2 patient — proceed with P2Y12 held per guideline timeline, aspirin continued, cardiology documented |
